I’m pretty certain I’m alive because I am white & was born into a middle class family in the US. Dr Upal Basu Roy & I often say while I/everyone deserves quality care, it’s hard to balance when much of what we advocate for will only reach ppl like me ‘a person of privilege’ 😔

Every CRC patient should be HER2 tested🧪. Final results of DESTINY-CRC01 investigating trastuzumab deruxtecan in patients with HER2-expressing metastatic colorectal cancer | Nature Communications nature.com/articles/s4146…

Final results of DESTINY-CRC01 investigating trastuzumab deruxtecan in HER2+ #CRC Nature Communications doi.org/10.1038/s41467… 👉ORR 45.3%, mPFS 6.9, mOS 15.5 and DoR 7.0 mo in IHC 3+/IHC 2+,ISH+ 👉Pneumonitis 9.3%, TEAEs ≥3 65% 👉sig. activity independent of prior 🎯💊 ESMO - Eur. Oncology

I❤️❤️being a thoracic oncologist: while our GI colleagues still struggle with folfox and folfiri 🥱we have numerous new exciting ⚡️& effective Tx 🔥 ADCs will soon be a part of our new routine so register to this webinar by IASLC with Daniel Tan Ben Levy and Toni Wozniak

Happy to present at #ESMO23 the results of #MBOT the first app 📱 for Ambulatory Malignant Bowel Obstruction management in #gynecancer Princess Margaret Cancer Centre Thanks to Conquer Cancer, the ASCO Foundation for making it possible through a #YIA grant

Correct! Anthracyclines were originally discovered in Italy approximately 70 years ago by a company named Farmitalia. A member of the team went on expedition to Castel del Monte, in Puglia, in which soil he identified a strain of Streptomyces producing a substance with

One of the most important trials presented and published in 2023

New germline genetic testing guidelines: All women with breast cancer diagnosis under the age of 65 should be offered germline genetic testing. They don’t need to meet any additional criteria. Thank you ASCO for the opportunity to draft these guidelines. ascopubs.org/doi/full/10.12…

A refreshing reflection on how we need to be change cancer categorization to allow treatment access. But how are we going to get equity in molecular cancer testing? Dr. Yvonne Bombard Forget lung, breast or prostate cancer: why tumour naming needs to change nature.com/articles/d4158…

Such an honor to be part of this great event! Thanks ESMO - Eur. Oncology for the opportunity.

How beautiful is to remember our own humanity in a world of institutional insanity. This is the only way to remember what really is meaningful 👨‍👩‍👧‍👦🥇🌟🗺️

Apply for the CRIS Cancer-Princess Margaret drug development fellowship CRIS contra el cáncer Princess Margaret Cancer Centre - great opportunity for those with interests in phase I trials and translational research criscancer.org/es/cris-prince…

📣 Do not miss this great e-Session on the newest data on DDR targeting agent ESOncology

Incredible presentation by Dr. Lheureux at ASCO 2024!

Very impressive results! Neoadjuvant Immunotherapy in Locally Advanced Mismatch Repair–Deficient Colon Cancer | New England Journal of Medicine ⁦NEJM⁩ nejm.org/doi/full/10.10…

Congrats Ainhoa! 🎉👏Outstanding PhD brilliantly presented! It was a real pleasure and honour to co-direct your thesis! Looking forward to continue working together!

🌟🌟🌟Exceptional educational discussion this morning in ESMO GYNE ESMO - Eur. Oncology #Florence The evolving la escape in endometrial cancer from staging to therapy. FIGO 2023, ADCs are approaching 💉 cslide.ctimeetingtech.com/gynae24hybrid/…

EUROCAN what a great example on what collaboration can achieve to improve management decisions for patients with rare gynecological cancers ESMO - Eur. Oncology #ESMOgynecologicalcancers2024 instagram.com/p/C8eLUueNqG4/…

A great practical presentation on Mirvetuximab in patients with platinum resistant ovarian cancers by my dear colleague🌟 Ainhoa Madariaga ESMO - Eur. Oncology

Dr. Chen Lee MBO management paradigm at ESMO Gynecological Cancers Stephanie Lheureux Nazlin Jivraj ESMO - Eur. Oncology